This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ciprofloxacin, Ciproxin
Description: The active ingredient in Cipro, ciprofloxacin, is a broad spectrum oral fluoroquinolone. Good activity is observed against Gram-(-) rods (E. coli, Proteus, Klebsiella, H. influenzae); moderate activity against Psuedomonas, Mycoplasma, Chlamydia, and Legionella; and poor activity against staphylococci, Streptococcus pneumoniae, anerobes, and enterococci.
The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
Deal Structure: Cipro was originally developed by Bayer AG.
In September 2004, Schering-Plough acquired exclusive rights from Bayer AG to market, sell and distribute Cipro in the United States and Puerto Rico.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Merck & Co and Schering-Plough announced that their merger completed on November 3, 2009.
Partners: Merck & Co., Inc.
Pink Sheet In Brief: Bayer's Cipro
Additional information available to subscribers only: